FDA’s Gottlieb slams drug makers for stalling release of biosimilars
Drug makers who manufacture pricey biologic medicines are relying on anti-competitive tactics, costing Americans billions, the FDA commissioner says.
WASHINGTON — Food and Drug Administration Commissioner Scott Gottlieb on Wednesday accused drug makers who manufacture pricey biologic medicines of using “unacceptable” anti-competitive tactics to keep competitors off the market, costing Americans billions.
The tactics — some of which Gottlieb will refer to as a “toxin” — have prevented other drug makers from launching , highly similar versions of the same
